title: Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience.
abstract: Ninety-eight pediatric patients were treated with three separate protocols (Treatment and investigation of Osteosarcoma [TIOS] I, II, and III) and 47 developed recurrent disease (metastases and/or local recurrence). Actuarial overall disease-free survival (hereafter designated survival) was 43%. Over 90% of the patients were treated initially with preoperative intraarterial cisplatin (CDP). Postoperative chemotherapeutic regimens comprised high-dose methotrexate with leucovorin rescue (MTX-CF), Adriamycin [( ADR] doxorubicin; Adria Laboratories, Columbus, OH), and cyclophosphamide. Primary definitive treatment comprised amputation or limb salvage (TIOS I and TIOS III). Patients treated with preoperative CDP and surgery (TIOS I and III) had a 62% survival. Patients in TIOS II refused surgical extirpation; they were treated exclusively with chemotherapy and had a 23% survival. Survival in patients treated with amputation was 55% and limb salvage 58%. Prognostic factors considered significant in relation to development of pulmonary metastases comprised tumor burden (P = .04) and the percentage of tumor necrosis induced by preoperative chemotherapy (P = .01). Histopathologic subtype was marginally significant: chondroblastic was more favorable as opposed to osteoblastic (P = .05). These findings are compared with results and prognostic factors published in the literature.
authors.affiliation: University of Texas MD Anderson Cancer Center, Department of Pediatrics, Houston 77030.
authors.forename: M
authors.initials: M
authors.lastname: Hudson
authors.forename: M R
authors.initials: MR
authors.lastname: Jaffe
authors.forename: N
authors.initials: N
authors.lastname: Jaffe
authors.forename: A
authors.initials: A
authors.lastname: Ayala
authors.forename: A K
authors.initials: AK
authors.lastname: Raymond
authors.forename: H
authors.initials: H
authors.lastname: Carrasco
authors.forename: S
authors.initials: S
authors.lastname: Wallace
authors.forename: J
authors.initials: J
authors.lastname: Murray
authors.forename: R
authors.initials: R
authors.lastname: Robertson
mesh_terms: D002648:Child; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000627:therapeutic use*; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local; D012516:Osteosarcoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D011379:Prognosis
chemical_list: D002945:Cisplatin; D002955:Leucovorin; D008727:Methotrexate